triterpene/inflammation

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the use of certain triterpenes which are inhibitors of nuclear factor kappa B (NF-.sub..kappa.B). In particular, it relates to useful triterpenes and pharmaceutical compositions containing them for use in the treatment

The present invention relates to two novel triterpene saponins, having antiinflammatory, mucolytic and antiedemic activity, of general formula ##STR2## wherein: R.sub.1 is H or OH, and R.sub.2 is a tetrasaccharide residue having 573 mass units or, alternatively, a pentasaccharide residue having 705

FIELD OF THE INVENTION The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises, as a first component, a diterpene triepoxide lactone species and,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NF.kappa.B, to methods of modulating inflammation, including in

CROSS-REFERENCE TO RELATED APPLICATIONS This application is filed under the provisions of 35 U.S.C. .sctn. 371 and claims the priority of International Patent Application No. PCT/EP2014/062269 filed on 12 Jun 2014 entitled "COMBINATION OF PENTACYCLIC TRITERPENES AND HYDROXYTYROSOL AND DERIVATIVES

BACKGROUND OF THE INVENTION The present invention relates to new products of pharmacological interest and, more specifically, to new derivatives of glycyrrhetinic acid characterized by their pharmacological effect as inhibitors of gastroduodenal ulcers. Glycyrrhetinic acid is prepared from

FIELD OF THE INVENTION The present invention relates generally to a composition exhibiting synergistic inhibition of the expression and/or activity of inducible cyclooxygenase-2 (COX-2). More particularly, the composition comprises, as a first component, a curcuminoid species and, as a second

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to at least the field of medicine. More specifically, it relates to compositions and methods regarding triterpene-coated stents. 2. Description of Related Art One of the leading causes of death in the